HRP20210417T1 - Pripravci magnezija namijenjeni moduliranju farmakokinetike i farmakodinamike inzulina, te boli na mjestu injekcije - Google Patents

Pripravci magnezija namijenjeni moduliranju farmakokinetike i farmakodinamike inzulina, te boli na mjestu injekcije Download PDF

Info

Publication number
HRP20210417T1
HRP20210417T1 HRP20210417TT HRP20210417T HRP20210417T1 HR P20210417 T1 HRP20210417 T1 HR P20210417T1 HR P20210417T T HRP20210417T T HR P20210417TT HR P20210417 T HRP20210417 T HR P20210417T HR P20210417 T1 HRP20210417 T1 HR P20210417T1
Authority
HR
Croatia
Prior art keywords
magnesium
insulin
acid
formulation according
concentration
Prior art date
Application number
HRP20210417TT
Other languages
English (en)
Croatian (hr)
Inventor
Roderike Pohl
Robert Hauser
Ming Li
Bryan R. Wilson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20210417T1 publication Critical patent/HRP20210417T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20210417TT 2012-04-16 2013-04-16 Pripravci magnezija namijenjeni moduliranju farmakokinetike i farmakodinamike inzulina, te boli na mjestu injekcije HRP20210417T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261624844P 2012-04-16 2012-04-16
US201261704066P 2012-09-21 2012-09-21
US13/826,806 US9381247B2 (en) 2012-04-16 2013-03-14 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
PCT/US2013/036742 WO2013158618A1 (en) 2012-04-16 2013-04-16 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
EP13721441.7A EP2838506B1 (en) 2012-04-16 2013-04-16 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin, and injection site pain

Publications (1)

Publication Number Publication Date
HRP20210417T1 true HRP20210417T1 (hr) 2021-04-30

Family

ID=48326401

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210417TT HRP20210417T1 (hr) 2012-04-16 2013-04-16 Pripravci magnezija namijenjeni moduliranju farmakokinetike i farmakodinamike inzulina, te boli na mjestu injekcije

Country Status (25)

Country Link
US (1) US9381247B2 (https=)
EP (2) EP2838506B1 (https=)
JP (2) JP6422855B2 (https=)
KR (1) KR101966484B1 (https=)
CN (1) CN104394847A (https=)
AU (1) AU2013249495B2 (https=)
CA (1) CA2869883A1 (https=)
CY (1) CY1123825T1 (https=)
DK (1) DK2838506T3 (https=)
ES (1) ES2854874T3 (https=)
HK (2) HK1207577A1 (https=)
HR (1) HRP20210417T1 (https=)
HU (1) HUE053303T2 (https=)
IL (1) IL234987A0 (https=)
IN (1) IN2014DN08417A (https=)
LT (1) LT2838506T (https=)
MX (1) MX2014012245A (https=)
PL (1) PL2838506T3 (https=)
PT (1) PT2838506T (https=)
RS (1) RS61533B1 (https=)
RU (1) RU2014145846A (https=)
SG (1) SG11201406491PA (https=)
SI (1) SI2838506T1 (https=)
WO (1) WO2013158618A1 (https=)
ZA (1) ZA201407410B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
KR102351111B1 (ko) * 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
WO2015120457A1 (en) * 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2016007935A2 (en) 2014-07-10 2016-01-14 Companion Medical, Inc. Medicine administering system including injection pen and companion device
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
KR20170106373A (ko) * 2015-01-20 2017-09-20 케이스 웨스턴 리저브 유니버시티 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US10864327B2 (en) 2016-01-29 2020-12-15 Companion Medical, Inc. Automatic medication delivery tracking
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP2019529506A (ja) 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
US11484657B2 (en) 2017-06-09 2022-11-01 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods
US11568975B2 (en) 2017-10-12 2023-01-31 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods for dose recommendation and management
JP7512203B2 (ja) 2017-12-12 2024-07-08 ビッグフット バイオメディカル インコーポレイテッド 治療支援情報及び/又は追跡装置並びに関連する方法及びシステム
US11083852B2 (en) 2017-12-12 2021-08-10 Bigfoot Biomedical, Inc. Insulin injection assistance systems, methods, and devices
US11197964B2 (en) 2017-12-12 2021-12-14 Bigfoot Biomedical, Inc. Pen cap for medication injection pen having temperature sensor
US11116899B2 (en) 2017-12-12 2021-09-14 Bigfoot Biomedical, Inc. User interface for diabetes management systems and devices
US10987464B2 (en) 2017-12-12 2021-04-27 Bigfoot Biomedical, Inc. Pen cap for insulin injection pens and associated methods and systems
US11464459B2 (en) 2017-12-12 2022-10-11 Bigfoot Biomedical, Inc. User interface for diabetes management systems including flash glucose monitor
US11077243B2 (en) 2017-12-12 2021-08-03 Bigfoot Biomedical, Inc. Devices, systems, and methods for estimating active medication from injections
US12357562B2 (en) 2018-04-04 2025-07-15 Arecor Limited Injection pen system for the delivery of an insulin compound
US11664107B2 (en) 2018-05-08 2023-05-30 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods using a prescription-regulated software application
US10898653B2 (en) 2018-05-08 2021-01-26 Companion Medical, Inc. Intelligent medication delivery systems and methods for dose setting and dispensing monitoring
USD893020S1 (en) 2018-05-11 2020-08-11 Companion Medical, Inc. Injection pen
USD892819S1 (en) 2018-06-20 2020-08-11 Companion Medical, Inc. Display screen with graphical user interface
US11587663B2 (en) 2018-06-20 2023-02-21 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods for medicine dose calculation and reporting
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
US12205699B1 (en) 2018-10-30 2025-01-21 Bigfoot Biomedical, Inc. Method of pairing therapy devices using shared secrets, and related systems, methods and devices
US11948671B2 (en) 2019-04-11 2024-04-02 Medtronic Minimed, Inc. Intelligent accessories for medicine dispensing device
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
US11701473B2 (en) 2021-06-23 2023-07-18 Medtronic Minimed, Inc. Reusable injection pens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2543249B1 (en) 2007-02-17 2018-05-23 President and Fellows of Harvard College Compositions and method for tissue preservation
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
CA2805031A1 (en) 2010-07-07 2012-01-12 Biodel, Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin

Also Published As

Publication number Publication date
ES2854874T3 (es) 2021-09-23
US9381247B2 (en) 2016-07-05
SG11201406491PA (en) 2014-11-27
EP2838506A1 (en) 2015-02-25
CY1123825T1 (el) 2022-05-27
EP3827813A1 (en) 2021-06-02
LT2838506T (lt) 2021-03-25
HUE053303T2 (hu) 2021-06-28
EP2838506B1 (en) 2021-01-06
KR101966484B1 (ko) 2019-04-05
ZA201407410B (en) 2015-06-24
JP2015512952A (ja) 2015-04-30
CA2869883A1 (en) 2013-10-24
SI2838506T1 (sl) 2021-02-26
WO2013158618A1 (en) 2013-10-24
CN104394847A (zh) 2015-03-04
HK1203371A1 (en) 2015-10-30
MX2014012245A (es) 2015-06-05
RS61533B1 (sr) 2021-04-29
DK2838506T3 (da) 2021-01-18
KR20140146209A (ko) 2014-12-24
IN2014DN08417A (https=) 2015-05-08
PT2838506T (pt) 2021-02-23
JP2019023223A (ja) 2019-02-14
HK1207577A1 (en) 2016-02-05
US20140113856A1 (en) 2014-04-24
IL234987A0 (en) 2014-12-31
RU2014145846A (ru) 2016-06-10
AU2013249495B2 (en) 2016-05-12
PL2838506T3 (pl) 2021-06-28
JP6422855B2 (ja) 2018-11-14

Similar Documents

Publication Publication Date Title
HRP20210417T1 (hr) Pripravci magnezija namijenjeni moduliranju farmakokinetike i farmakodinamike inzulina, te boli na mjestu injekcije
JP2015512952A5 (https=)
MY159488A (en) Dentifrice comprising stannous fluoride plus zinc citrate and low levels of water
HRP20181035T1 (hr) Formulacije inzulina za brzi unos
HRP20200889T1 (hr) Upotreba dugodjelujućih peptida glp-1
MX354637B (es) Composiciones de limpieza personal conteniendo haluro de aminoacido/trimetilglicina y zinc.
AR086651A1 (es) Dentifrico de ion metalico con bajo contenido de agua
MY169816A (en) Ophthalmic solution comprising diquafosol
BRPI1009652A2 (pt) tecidos anticrobianos compreendendo peróxido
HRP20250025T1 (hr) Visoko koncentrirani sastavi antitijela
MY157021A (en) Oral care product and methods of use thereof
MY161930A (en) Antipsychotic injectable depot composition
MX339909B (es) Composiciones para el cuidado bucal que comprende acido fitico.
ZA201007185B (en) Aqueous pharmaceutical formulation
MX350255B (es) Agentes quimicos y biologicos para el control de moluscos.
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
EA201490175A1 (ru) Составы дезоксихолевой кислоты и ее солей
MY161032A (en) Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
BR112013030068A2 (pt) grânulos de controle biológico estabilizados dispersíveis em água
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
MX2016005339A (es) Composicion antitranspirante.
AR075567A1 (es) Composicion antimicrobiana.
IN2014DN09297A (https=)
GB2497680A (en) Compositions and methods for mitigating adverse effects of exposure to chlorinating and/or brominating agents
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt